Clinical Trials Logo

Immune Thrombocytopenic Purpura clinical trials

View clinical trials related to Immune Thrombocytopenic Purpura.

Filter by:

NCT ID: NCT03177629 Recruiting - Clinical trials for Immune Thrombocytopenia

H. Pylori Eradication for Moderate ITP

Start date: May 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of H. pylori eradication for the treatment of chronic or persistent immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia. This is a multi-center, open label, prospective randomized phase IIl study.

NCT ID: NCT02273960 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

ITP
Start date: November 17, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.

NCT ID: NCT02085993 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training

Start date: July 2014
Phase: N/A
Study type: Observational

Cross-sectional study, observation made by healthcare professionals of subjects or caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after training with the home administration training pack. Further observations can also be recorded in the study if made within 16 weeks of enrolment. Data will be collected from the subjects' dose diary at their first standard of care visit to ensure there were no problems with administration while not at the clinic.

NCT ID: NCT02077192 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start date: October 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP

NCT ID: NCT02076412 Completed - Clinical trials for Immune Thrombocytopenic Purpura

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

FIT
Start date: January 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

NCT ID: NCT02076399 Completed - Clinical trials for Immune Thrombocytopenic Purpura

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

FIT
Start date: July 14, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

NCT ID: NCT01730352 Completed - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients

Start date: October 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.

NCT ID: NCT01719692 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

ITP
Start date: October 2012
Phase: N/A
Study type: Interventional

A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

NCT ID: NCT01713855 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Start date: October 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.

NCT ID: NCT01672151 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

ITP
Start date: November 2011
Phase: N/A
Study type: Observational

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.